These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 18056332)
1. 18F-FDG PET/CT in evaluating non-CNS pediatric malignancies. Tatsumi M; Miller JH; Wahl RL J Nucl Med; 2007 Dec; 48(12):1923-31. PubMed ID: 18056332 [TBL] [Abstract][Full Text] [Related]
2. Clinical impact of "true whole-body" (18)F-FDG PET/CT: lesion frequency and added benefit in distal lower extremities. Kawata S; Imaizumi M; Kako Y; Oku N Ann Nucl Med; 2014 May; 28(4):322-8. PubMed ID: 24488705 [TBL] [Abstract][Full Text] [Related]
3. Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography. Gatidis S; Schmidt H; Gücke B; Bezrukov I; Seitz G; Ebinger M; Reimold M; Pfannenberg CA; Nikolaou K; Schwenzer NF; Schäfer JF Invest Radiol; 2016 Jan; 51(1):7-14. PubMed ID: 26309185 [TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional Imaging. Lopci E; Burnelli R; Ambrosini V; Nanni C; Castellucci P; Biassoni L; Rubello D; Fanti S Cancer Biother Radiopharm; 2008 Dec; 23(6):681-90. PubMed ID: 19111053 [TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736 [TBL] [Abstract][Full Text] [Related]
6. Utility of FDG-PETCT and magnetic resonance spectroscopy in differentiating between cerebral lymphoma and non-malignant CNS lesions in HIV-infected patients. Westwood TD; Hogan C; Julyan PJ; Coutts G; Bonington S; Carrington B; Taylor B; Khoo S; Bonington A Eur J Radiol; 2013 Aug; 82(8):e374-9. PubMed ID: 23578921 [TBL] [Abstract][Full Text] [Related]
7. The incremental value of 18F-FDG PET/CT in paediatric malignancies. Bar-Sever Z; Keidar Z; Ben-Barak A; Bar-Shalom R; Postovsky S; Guralnik L; Ben Arush MW; Israel O Eur J Nucl Med Mol Imaging; 2007 May; 34(5):630-637. PubMed ID: 17048034 [TBL] [Abstract][Full Text] [Related]
8. Usefulness and pitfalls of F-18-FDG PET/CT for diagnosing extramedullary acute leukemia. Zhou WL; Wu HB; Wang LJ; Tian Y; Dong Y; Wang QS Eur J Radiol; 2016 Jan; 85(1):205-210. PubMed ID: 26724667 [TBL] [Abstract][Full Text] [Related]
9. Hodgkin disease: diagnostic value of FDG PET/CT after first-line therapy--is biopsy of FDG-avid lesions still needed? Schaefer NG; Taverna C; Strobel K; Wastl C; Kurrer M; Hany TF Radiology; 2007 Jul; 244(1):257-62. PubMed ID: 17581905 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic accuracy and prognostic value of 18F-FDG PET in Hürthle cell thyroid cancer patients. Pryma DA; Schöder H; Gönen M; Robbins RJ; Larson SM; Yeung HW J Nucl Med; 2006 Aug; 47(8):1260-6. PubMed ID: 16883003 [TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma. Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575 [TBL] [Abstract][Full Text] [Related]
12. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up. Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of optimal acquisition duration or injected activity for pediatric 18F-FDG PET/CT. Alessio AM; Sammer M; Phillips GS; Manchanda V; Mohr BC; Parisi MT J Nucl Med; 2011 Jul; 52(7):1028-34. PubMed ID: 21680684 [TBL] [Abstract][Full Text] [Related]
14. Post-treatment surveillance of head and neck cancer: pitfalls in the interpretation of FDG PET-CT/MRI. Meerwein CM; Queiroz M; Kollias S; Hüllner M; Veit-Haibach P; Huber GF Swiss Med Wkly; 2015; 145():w14116. PubMed ID: 25701645 [TBL] [Abstract][Full Text] [Related]
15. 18F-FDG PET and PET/CT in Burkitt's lymphoma. Karantanis D; Durski JM; Lowe VJ; Nathan MA; Mullan BP; Georgiou E; Johnston PB; Wiseman GA Eur J Radiol; 2010 Jul; 75(1):e68-73. PubMed ID: 19716248 [TBL] [Abstract][Full Text] [Related]
16. The value of 18F-FDG PET in pediatric patients with post-transplant lymphoproliferative disorder at initial diagnosis. Vali R; Punnett A; Bajno L; Moineddin R; Shammas A Pediatr Transplant; 2015 Dec; 19(8):932-9. PubMed ID: 26515450 [TBL] [Abstract][Full Text] [Related]
17. Comparative study of FDG PET/CT and conventional imaging in the staging of rhabdomyosarcoma. Tateishi U; Hosono A; Makimoto A; Nakamoto Y; Kaneta T; Fukuda H; Murakami K; Terauchi T; Suga T; Inoue T; Kim EE Ann Nucl Med; 2009 Feb; 23(2):155-61. PubMed ID: 19225939 [TBL] [Abstract][Full Text] [Related]
18. Impact of 18F-FDG PET/CT with retrograde filling of the urinary bladder in patients with suspected pelvic malignancies. Vicente AM; Castrejón AS; Muñoz AP; Woll PP; García AN J Nucl Med Technol; 2010 Sep; 38(3):128-37. PubMed ID: 20807854 [TBL] [Abstract][Full Text] [Related]